The AQUA-FONTIS study: protocol of a multidisciplinary, cross-sectional and prospective longitudinal study for developing standardized diagnostics and classification of non-thyroidal illness syndrome

1472-6823-8-13 1472-6823 Study protocol The AQUA-FONTIS study: protocol of a multidisciplinary, cross-sectional and prospective longitudinal study for developing standardized diagnostics and classification of non-thyroidal illness syndrome Dietrich W Johannes johannes.dietrich@ruhr-uni-bochum.de Stachon Axel axel.stachon@ruhr-uni-bochum.de Antic Biljana Biljana.Antic@web.de Klein H Harald harald.klein@bergmannsheil.de Hering Steffen steffen.hering@ruhr-uni-bochum.de

Medical Hospital 1, Bergmannsheil University Hospitals, Ruhr University of Bochum, Bochum, NRW, Germany

Institute of Clinical Chemistry, Transfusion and Laboratory Medicine, Bergmannsheil University Hospitals, Ruhr University of Bochum, Bochum, NRW, Germany

Klinik für Innere Medizin, Evangelisches Krankenhaus Hattingen, Hattingen, NRW, Germany

BMC Endocrine Disorders 1472-6823 2008 8 1 13 http://www.biomedcentral.com/1472-6823/8/13 18851740 10.1186/1472-6823-8-13 05 9 2008 13 10 2008 13 10 2008 2008 Dietrich et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background

Non-thyroidal illness syndrome (NTIS) is a characteristic functional constellation of thyrotropic feedback control that frequently occurs in critically ill patients. Although this condition is associated with significantly increased morbidity and mortality, there is still controversy on whether NTIS is caused by artefacts, is a form of beneficial adaptation, or is a disorder requiring treatment. Trials investigating substitution therapy of NTIS revealed contradictory results. The comparison of heterogeneous patient cohorts may be the cause for those inconsistencies.

Objectives

Primary objective of this study is the identification and differentiation of different functional states of thyrotropic feedback control in order to define relevant evaluation criteria for the prognosis of affected patients. Furthermore, we intend to assess the significance of an innovative physiological index approach (SPINA) in differential diagnosis between NTIS and latent (so-called "sub-clinical") thyrotoxicosis.

Secondary objective is observation of variables that quantify distinct components of NTIS in the context of independent predictors of evolution, survival or pathophysiological condition and influencing or disturbing factors like medication.

Design

The approach to a quantitative follow-up of non-thyroidal illness syndrome (AQUA FONTIS study) is designed as both a cross-sectional and prospective longitudinal observation trial in critically ill patients. Patients are observed in at least two evaluation points with consecutive assessments of thyroid status, physiological and clinical data in additional weekly observations up to discharge. A second part of the study investigates the neuropsychological impact of NTIS and medium-term outcomes.

The study design incorporates a two-module structure that covers a reduced protocol in form of an observation trial before patients give informed consent. Additional investigations are performed if and after patients agree in participation.

Trial Registration

ClinicalTrials.gov NCT00591032

Background

Non-thyroidal illness syndrome (NTIS or euthyroid sick syndrome) is a complex endocrine condition that may occur in critically ill patients. It is associated with significant deterioration of prognosis.

NTIS is characterised by three components that may occur single or in combination:central hypothyroidism (transient thyrotropic insufficiency), impaired protein binding of thyroid hormones and reduced formation of T3 with simultaneously increased conversion to rT3 (low-T3-syndrome) 12.

In 1973, characteristic alterations of thyroid metabolism have been first described in the starving organism 34. Additional observations could reveal that these alterations are also common in critically ill patients where they form the correlate of endocrine dysregulation with increased morbidity and mortality 5678.

However, explanation concepts for this complex constellation are different. Up to now, in essence five hypotheses are discussed in literature 2:

1. All observed abnormalities are the result of test artefacts. In reality, the patients are euthyroid.

2. The changes in the levels of peripheral thyroid hormones mirror the effect of certain binding inhibitors that influence

A) laboratory results only or

B) also the transfer of thyroid hormones into the tissue of diseased persons and thus diminish binding of iodothyronines to T3 receptors.

3. Due to increased local deiodation, T3-levels are normal in the pituitary gland while they are low in the rest of the organism.

4. Levels of peripheral thyroid hormones are actually low so that affected patients are biochemically hypothyroid. However, this useful physiological function should not be manipulated.

5. NTIS is secondary or tertiary hypothyroidism. The resulting tissue hypothyroidism should be treated with appropriate substitution therapy 2.

Despite of intensive and long lasting research to many of its details NTIS is still poorly characterized in an integrative view. Additionally, a clinically usable classification is lacking.

Given the fact that patients with NTIS are faced with poor prognosis, several studies have been conducted in the past evaluating the question of possible treatment 27. However, they did not yield unambiguous results. Some studies could show a benefit of substitution therapy with thyroid hormones, e.g. regarding the incidence of atrial fibrillation 27910 and hemodynamic parameters 1112 while others could not observe relevant differences in outcome between treated and untreated patients 131415. Several studies even described detrimental effects of substitution therapy ranging from increased risk of hyperthyroidism 1617 over undesirably high protein catabolism 18 to severe side effects in patients with adrenal insufficiency that may be difficult to identify during critical illness 19. Recently, a small trial investigating the effect of selenium substitution on the development of critically ill patients demonstrated improvements in prognosis, but, in spite of the known selenium-dependency of peripheral deiodinases, this outcome was not caused by a direct effect on thyroid homeostasis 20.

The problem of inconclusive and partly contradictory study results is aggravated by the fact that there is no consistent definition of NTIS that delimits this constellation from euthyroid state and that weighs the associated components regarding their relevance. Therefore, it may be assumed that the mentioned studies compared inhomogeneous patient groups.

An additional challenge affecting clinical practice is the fact that partial thyrotropic insufficiency in the course of NTIS can hardly be distinguished from latent ("subclinical") hyperthyroidism – although pathophysiology and therapeutic implications are opposed.

Objectives of the AQUA FONTIS project

The AQUA FONTIS study (approach to a quantitative follow-up of non-thyroidal illness syndrome) is primarily intended to develop a clear-cut definition and classification of NTIS (Table 1). Overall, this project is proposed to deliver a prognostic aid by providing a differentiated classification, to contribute to a standardised, rational and inexpensive diagnostic procedure in form of quantitative indices, and to lay the foundation for future therapeutic trials by identifying subgroups that may benefit from therapy.

Table 1

Proposed "HPD" classification

Facet

Possible values

Hypothalamic-pituitary dysfunction or adaptation ("H")

H0: Normal TSH secretion, adequate to T4 level

H1: Thyrotropic insufficiency

Impaired plasma protein binding ("P")

P0: Normal binding to plasma proteins

P1: Normal binding with reduced levels of plasma proteins

P2: reduced binding to proteins within normal levels

P3: reduced binding and reduced protein levels

Reduced deiodation ("D")

D0: Normal deiodation

D1: Reduced deiodation activity

Example: H1P0D1: Thyrotropic insufficiency with reduced deiodation and normal protein binding.

Outcome measure of this primary objective is the comparison of different decision criteria as presented in Table 2. These criteria are assessed with regard to the prognosis of the patients. Additionally, the significance of an innovative physiological index approach (SPINA) 21 is to be evaluated regarding its applicability for differential diagnosis between NTIS and latent thyrotoxicosis. It will therefore be evaluated in terms of sensitivity, specificity and likelihood ratios with ROC analysis.

Table 2

Decision criteria

Criterion

Definition

Thyrotropic insufficiency

a) Reduced levels of both TSH and free T4.

b) Thyrotroph T4 Sensitivity Index (TTSI) reduced below its reference interval.

Reduced plasma protein binding

a) Reduced relative ratios of bound and free hormone levels

b) Reduced apparent dissociation constant of T3 at thyroxin binding globulin (K₃₀)

Reduced deiodation

a) Reduced level for free T3

b) diminished T3/T4-ratio

c) reduced sum activity of peripheral 5'-Dejodinase (G_D^)

As secondary objective, we plan to observe variables that quantify distinct components of NTIS in the context of independent predictors of evolution, survival or pathophysiological condition as well as influencing or disturbing factors like medication or medical procedures. Outcome measures are correlations between quantitatively described components and external factors as well as their distributions in the context of dichotomic influencing factors.

Methods

The AQUA FONTIS study is designed as both a cross-sectional and prospective longitudinal observation trial (Figure 1).

Figure 1

Flowchart of the AQUA-FONTIS study with its two intertwined modules

Flowchart of the AQUA-FONTIS study with its two intertwined modules. See text and table 5 for detailed information.

Recruitment and criteria for inclusion and exclusion

This study recruits critically ill patients treated in one medical and two surgical intensive care units of the Bergmannsheil University hospitals for evaluation of integrative thyrotropic control and follow-up. Inclusion and exclusion criteria are presented in table 3. The diagnostic criteria are based on the ICD-10 system 22.

Table 3

Inclusion and exclusion criteria of the AQUA FONTIS study

Inclusion

Exclusion

Severe illness requiring intensive care

Substituted hypothyroidism (E03.0, E03.1, E03.3 E03.9, E89.0) or substitution in case of thyroid carcinoma (C73)

Stay of at least 24 hours at the ICU

Hyperthyroidism treated with thyrostatic agents and exhibiting a TSH level not below the reference region (E05.0 E05.9, E06.2)

Manifest AIDS disease (B24)

Pregnancy

Decision criteria

Latent (so called "subclinical") thyrotoxicosis is defined as suppressed thyrotropin levels with free T4 levels being in their reference intervals and additional clinical evidence for tissue hyperthyroidism (suggestive history or Burch-Wartofsky point scale of more than 45 points 23). Decision criteria to be evaluated are reproduced in Table 2.

Calculations

Thyrotroph T4 Sensitivity Index (TTSI) is calculated as

T T S I = 100 [ T S H ] [ F T 4 ] l u MathType@MTEF@5@5@+=feaagaart1ev2aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacPC6xNi=xI8qiVKYPFjYdHaVhbbf9v8qqaqFr0xc9vqFj0dXdbba91qpepeI8k8fiI+fsY=rqGqVepae9pg0db9vqaiVgFr0xfr=xfr=xc9adbaqaaeGaciGaaiaabeqaaeqabiWaaaGcbaGaemivaqLaemivaqLaem4uamLaemysaKKaeyypa0tcfa4aaSaaaeaacqaIXaqmcqaIWaamcqaIWaamcqGGBbWwcqWGubavcqWGtbWucqWGibascqGGDbqxcqGGBbWwcqWGgbGrcqWGubavdaWgaaqaaiabisda0aqabaGaeiyxa0fabaGaemiBaW2aaSbaaeaacqWG1bqDaeqaaaaaaaa@440A@

with l_ubeing the upper limit of the reference interval for free T4 24. Theoretical secretion capacity of the thyroid gland (G_T^) is computed with

G ^ T = β T ( D T + [ T S H ] ) ( 1 + K 41 [ T B G ] + K 42 [ T B P A ] ) [ F T 4 ] α T [ T S H ] , MathType@MTEF@5@5@+=feaagaart1ev2aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacPC6xNi=xI8qiVKYPFjYdHaVhbbf9v8qqaqFr0xc9vqFj0dXdbba91qpepeI8k8fiI+fsY=rqGqVepae9pg0db9vqaiVgFr0xfr=xfr=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@655A@

where parameters are taken from Table 421.

Table 4

Parameters for structure parameter inference 21

Symbol

Explanation

Value

α_T

Dilution factor for T4 (reciprocal of apparent volume of distribution)

0,1 l^-1

β_T

Clearance exponent for T4

1,1 * 10^-6sec^-1

D_T

EC₅₀for TSH

2,75 mU/l

K₄₁

Dissociation constant T4-TBG

2 * 10¹⁰l/mol

K₄₂

Dissociation constant T4-TBPA

2 * 10⁸l/mol

α ₃₁

Dilution factor for T3

0,026 l^-1

β ₃₁

Clearance exponent for T3

8 * 10^-6sec^-1

K_M1

Dissociation constant of type-1-deiodinase

5 * 10^-7mol/l

K₃₀

Dissociation constant T3-TBG

2 * 10⁹l/mol

Sum activity of peripheral 5'-deiodinase (G_D^) is defined with

G ^ D = β 31 ( K M 1 + [ F T 4 ] ) ( 1 + K 30 [ T B G ] ) [ F T 3 ] α 31 [ F T 4 ] , MathType@MTEF@5@5@+=feaagaart1ev2aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacPC6xNi=xI8qiVKYPFjYdHaVhbbf9v8qqaqFr0xc9vqFj0dXdbba91qpepeI8k8fiI+fsY=rqGqVepae9pg0db9vqaiVgFr0xfr=xfr=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@5C56@

parameters are again from Table 421.

Apparent dissociation constant of T3 binding to TBG is obtained with

K ^ 30 = [ T 3 ] − [ F T 3 ] [ T B G ] [ F T 3 ] MathType@MTEF@5@5@+=feaagaart1ev2aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacPC6xNi=xI8qiVKYPFjYdHaVhbbf9v8qqaqFr0xc9vqFj0dXdbba91qpepeI8k8fiI+fsY=rqGqVepae9pg0db9vqaiVgFr0xfr=xfr=xc9adbaqaaeGaciGaaiaabeqaaeqabiWaaaGcbaGafm4saSKbaKaadaWgaaWcbaGaeG4mamJaeGimaadabeaakiabg2da9KqbaoaalaaabaGaei4waSLaemivaq1aaSbaaeaacqaIZaWmaeqaaiabc2faDjabgkHiTiabcUfaBjabdAeagjabdsfaunaaBaaabaGaeG4mamdabeaacqGGDbqxaeaacqGGBbWwcqWGubavcqWGcbGqcqWGhbWrcqGGDbqxcqGGBbWwcqWGgbGrcqWGubavdaWgaaqaaiabiodaZaqabaGaeiyxa0faaaaa@484C@

from levels of iodothyronines and TBG.

Relative binding ratio is calculated with

R B = [ T 3 ] l l , T T 3 [ F T 3 ] l l , F T 3 MathType@MTEF@5@5@+=feaagaart1ev2aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacPC6xNi=xI8qiVKYPFjYdHaVhbbf9v8qqaqFr0xc9vqFj0dXdbba91qpepeI8k8fiI+fsY=rqGqVepae9pg0db9vqaiVgFr0xfr=xfr=xc9adbaqaaeGaciGaaiaabeqaaeqabiWaaaGcbaGaemOuai1aaSbaaSqaaiabdkeacbqabaGccqGH9aqpjuaGdaWcaaqaamaalaaabaGaei4waSLaemivaq1aaSbaaeaacqaIZaWmaeqaaiabc2faDbqaaiabdYgaSnaaBaaabaGaemiBaWMaeiilaWIaemivaqLaemivaqLaeG4mamdabeaaaaaabaWaaSaaaeaacqGGBbWwcqWGgbGrcqWGubavdaWgaaqaaiabiodaZaqabaGaeiyxa0fabaGaemiBaW2aaSbaaeaacqWGSbaBcqGGSaalcqWGgbGrcqWGubavcqaIZaWmaeqaaaaaaaaaaa@490E@

where l_{l, TT3}denotes the lower limit of the reference interval for TT3 and l_{l, FT3}is the lower limit of the reference interval for FT3.

Follow-up and Evaluation Points

Patients are subjected to at least one evaluation point. Critically ill persons that are newly admitted to an ICU are screened in the first EP (1.0) for fulfilment of the inclusion and exclusion criteria from Table 3 and entered in the database (see below). The second EP (1.1) is performed after 24 hours; only those eligible patients that are still under intensive care will be included in the study and subsequently prospectively observed. On the occasion of this and the subsequent EPs (after 72 hours for EP 1.2 and weekly in the further course of the study), severity scores like SAPS II and APACHE II as well as physiological parameters and data regarding pharmacological therapy or medical interventions are surveyed (Table 5). Additionally, laboratory investigations that are part of routine diagnostics (e.g. TSH, FT4, total T3, inflammation parameters, total protein etc.) are complemented by those parameters that are collected for the study (total T4, free T3 and antibodies against iodothyronines as well as thyroid tissue). As all required specimens are taken in the course of routine diagnostic procedures, additional assays, but no additional blood samples are necessary.

Table 5

Schedule of evaluation points

EP 1.0

EP 1.1

EP 1.2

EP 1.3

EP 1.999

Screening

After 24 hours

After 72 hours

Weekly

After discharge

Screening

Inclusion and Exclusion criteria

•

Informed consent

Demography

Age, Gender

•

History

•

Laboratory examinations

TSH, TT4, FT4, TT3, FT3

•

rT3

•

Total protein, Albumin

•

BC, CRP, ATIII, Fibrinogen

•

Thyroid antibodies, T4/T3-Abs.

•

Other investigations

•

Temperature, Horowitz-Quotient

Vital signs

•

Evolution data

Medication

•

APACHE-II-/SAPS-II-Score, GCS

•

Diagnosis

•

HD/CVVH/CVVHDF

•

IABP

•

Persistent organ failure

•

Outcome (survival etc.)

•

EP 2.0

EP 2.1

EP 2.2

EP 2.3

After transfer to peripheral ward

After 3 months

After 6 months

After 1 year

History and clinical data

Burch-Wartofsky score

Medication

Vital signs

Laboratory examinations

TSH, TT4, FT4, TT3, FT3

Neuropsychological data

Number connection test

RWT

SKT

HADS

SF36

Other investigations

Thyroid ultrasonography

Outcome (survival etc.)

•: Scheduled at indicated EP.

°: Scheduled after transfer to peripheral ward.

When patients have been transferred to a peripheral ward they are subjected to a single additional evaluation point (EP 2.0) surveying neuropsychological data covering anxiety, depression, speed of information processing and memory (see second part of Table 5). After discharge, they will be invited to repeated neuropsychological evaluations after 3, 6 and 12 months. This second part of the study is restricted to patients that gave informed consent (see below) and that have the mental and somatic ability to take part in this sub-study.

Patients that are admitted to an ICU a second time will only be observed up to that date, i.e. follow-up observation will stop after readmission to the ICU.

Sample size and power calculation

The AQUA-FONTIS study has a planned sample size of 650 patients. On the premise of a beta level of 0.1 (corresponding to a power of 0.9), an alpha level of 0.05, and standard deviations and event rates as observed in the literature and in this study to date, between 200 and 566 patients would be required, depending on the objective in question.

With an appropriate safety-margin a total required number of 650 patients results. Most questions could be answered with 500 patients, however.

Data management

Data are stored as electronic case report forms (eCRF) on a Macintosh server in a network-based relational database that has been developed with FileMaker Pro 5.5 (FileMaker, Inc., Santa Clara, CA, USA). It accommodates important principles of data protection by the fact that patient data are stored in pseudonymised form, i.e. they are referred to by number only, while mapping to patient names is only possible with an external list that is stored separately from the database. Additionally, the server is operating in the hospital's intranet with access from outside being blocked by a firewall. Data security is provided by a combination of established methods that cover regular backups and archiving as well as galvanic isolation of the server by an uninterruptible power supply. Operation of the server in a locked, dedicated room that is inaccessible for unauthorized persons serves both data protection and data security.

Other benefits of this database-founded approach are the ability to store very large amounts of information and the option to enter data from several wards simultaneously.

Statistics

The main null-hypothesis to be tested is that the decision-criteria presented in Table 2 lead to results that are independently distributed from the prognosis of included patients. Risk stratification will be performed with log rank test and Cox regression; end points are mortality, length of stay in hospital (LOSIH), length of stay in intensive care unit (LOSICU) and ability to work after discharge.

Cross sectional analysis will be done with the chi-squared test (for categorial data) and Student's t-test (for continuous data).

Multivariate regression analysis will be used to investigate correlation between quantitatively determined components of thyroid homeostasis and influencing pathophysiological factors.

Missing data analysis will be performed with "modern" procedures like EM algorithm and multiple imputation 25, if required.

Ethical considerations

For various reasons, most critically ill patients are not able to give informed consent 2627. We therefore restricted investigations in the first part of the trial to observation and laboratory tests from sera that have been obtained for routine diagnostics independently from this study, therefore not requiring extra-specimens. In essence, the reduced sub-protocol is designed in form of an observational study that resembles epidemiological investigations; this part of the study is therefore not subject of the German law governing clinical trials of drugs and medicinal products (Arzneimittelgesetz) and the corresponding European directives 2001/20/EC and 2005/28/EC 282930.

After being transferred to a peripheral ward, each participant receives information about the trial both verbally and in written form. Continued participation is voluntary, without expected negative side effects, and the patient can withdraw his or her consent at any time for parts of the study (e.g. future evaluation points) or the whole trial without consequence for treatment possibilities. All patients will receive a copy of their rights.

Patients that are never able to give consent, e.g. because they die before regaining consciousness, or that acquire permanent brain damage, only traverse the simplified procedure of the reduced observational protocol as described above. The same holds true for patients that have been discharged or transferred to an external hospital before being asked for consent, or that are not able to communicate in German.

The local ethics committee of the Ruhr-University of Bochum has approved the protocol under the file number 2848. The trial is registered at ClinicalTrials.gov as NCT00591032.

Both significant and insignificant findings from the trial will be published, in accordance with the STROBE statement 31. Links to publications will be made available on the study-website http://www.aqua-fontis.eu.

Status of the study

Up to now, 561 patients have been screened, 470 persons are included in the study, corresponding to 72% of the planned sample size.

In this unselected sample, currently 210 females (37%) have been observed, the ages of included patients ranging between 9 and 96 years. 61% of patients were screened from the two surgical ICUs, 39% from the medical ICU.

Discussion

The approach to a quantitative follow-up of non-thyroidal illness syndrome (AQUA-FONTIS study) has been designed to develop standardised diagnostic and classification criteria for NTIS. Apart from identification and differentiation of distinct functional states of thyrotropic feedback control in the context of critical illness, this study will help to assess the correlation of variables that quantify the components of NTIS with independent predictors of evolution, survival or pathophysiological condition. Additionally, it will evaluate the effect of influencing or disturbing factors like medication or interventional procedures.

In the past, many studies dealt with the impact of severe diseases on thyroid metabolism 12345678. However, they had inconsistent results, which may be the result of lacking standardised criteria. The objective of the AQUA FONTIS project is to provide more clear-cut decision criteria for prognosis and possibly therapy of affected patients. These may help to make future studies comparable.

However, also the AQUA FONTIS study is faced with several limitations. These predominantly accrue from the fact that most patients receiving intensive care are not able to give informed consent 2632. We therefore had to constrain the possible investigations to methods that are purely observational or use patient sera that were obtained for routine diagnostics. Due to their extensive ethical and legal implications, we were e.g. not able to investigate genetic aspects of NTIS without informed consent: Although deferred consent for genetic investigations could be obtained from surviving patients this is by nature not possible in persons that are admitted as emergency cases and die early, so that a relevant bias would be to expect 27.

Additionally, the fact that a high proportion of patients will be admitted in cases of accidents or emergency makes it difficult to control relevant influencing factors. Conditions like existing thyroid diseases or previous medication may therefore in some cases be missed. Furthermore, stratification will be impossible.

These restrictions are shared by all observational studies. Alternative forms of data acquisition may seem more appropriate from a pure statistical point of view. However, the mentioned medical and ethical marginal conditions render them impossible.

Its two-module structure, covering an observational part before patients gave consent and a more comprehensive sub-study that is traversed after consent was obtained, helps to overcome some of the limitations of the AQUA FONTS study. Additionally, the number of patients that could already be included up to now gives reason to believe that some of the poorly controllable influencing factors may partly be compensated by a large final case number. We are therefore convinced that this study will help to identify decision-parameters for defining states of particular importance with respect to the prognosis of affected patients. These may lay the basis for future epidemiological or therapeutic trials.

Abbreviations

APACHE: acute physiology and chronic health evaluation; AQUA FONTIS: approach to a quantitative follow-up of non-thyroidal illness syndrome; BWPS: Burch-Wartofsky point scale; eCRF: electronic case report form; EP: evaluation point; GCS: Glasgow come scale; HADS: hospital anxiety and depression scale; ICU: intensive care unit; LOSICU: length of stay in intensive care unit; LOSIH: length of stay in hospital; NTIS: non-thyroidal illness syndrome; rT3: reverse triiodothyronine; RWT: Regensburger Wortflüssigkeitstest (Regensburg word fluidity test); SF36: short form with 36 items; SKT: Syndrom-Kurztest (syndrome short evaluation); SPINA: structure parameter inference approach; T3: triiodothyronine; T4: levothyroxine; TSH: thyrotropin; TTSI: thyrotroph T4 sensitivity index.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

All authors were involved in conception and design of the study protocol, drafting or revising the manuscript, and have approved the final manuscript. JWD is responsible for performing evaluation points, data analysis and overall coordination. AS is responsible for laboratory assays, SH and HHK are co-responsible for data analysis. BA was in the planning phase of the study responsible for the development of the ethical conception. All authors will participate in interpretation of results.

Acknowledgements

The study has received funding by the science commission of the Bergmannsheil University hospitals, Bochum.

The authors would like to thank the members of the local ethics committee of the Ruhr-University of Bochum for valuable suggestions.

Dynamic neuroendocrine responses to critical illness Berghe Van den G Front Neuroendocrinol 2002 23 370 391 10.1016/S0091-3022(02)00006-7 12381331 Non-thyroidal illness syndrome is a manifestation of hypothalamic-pituitary dysfunction, and in view of current evidence, should be treated with appropriate replacement therapies De Groot LJ Crit Care Clin 2006 22 57 86 10.1016/j.ccc.2005.10.001 16399020 The influence of total starvation on the pituitary-thyroid-axis in obese individuals Rothenbuchner G Loos U Kiessling WR Birk J Pfeiffer EF Acta Endocrinol Suppl (Copenh) 1973 173 144 4542076 The effect of starvation on the concentration and binding of thyroxine and triiodothyronine in serum and on the response to TRH Portnay GI O'Brian JT Bush J Vagenakis AG Azizi F Arky RA Ingbar SH Braverman LE J Clin Endocrinol Metab 1974 39 191 194 4835133 Nonthyroidal illness syndrome or euthyroid sick syndrome? Chopra IJ Endocr Pract 1996 2 45 52 15251561 Low-T3 syndrome: a strong prognostic predictor of death in patients with heart disease Iervasi G Pingitore A Landi P Raciti M Ripoli A Scarlattini M L'Abbate A Donato L Circulation 2003 107 708 713 10.1161/01.CIR.0000048124.64204.3F 12578873 Dangerous dogmas in medicine: the nonthyroidal illness syndrome De Groot LJ J Clin Endocrinol Metab 1999 84 151 164 10.1210/jc.84.1.151 9920076 Low triiodothyronine (T3) state: a predictor of outcome in respiratory failure? Results of a clinical pilot study Scoscia E Baglioni S Eslami A Iervasi G Monti S Todisco T Eur J Endocrinol 2004 151 557 560 10.1530/eje.0.1510557 15538932 Triiodothyronine therapy lowers the incidence of atrial fibrillation after cardiac operations Klemperer JD Klein IL Ojamaa K Helm RE Gomez M Isom OW Krieger KH Ann Thorac Surg 1996 61 1323 1327 10.1016/0003-4975(96)00102-6 8633935 Thyroid hormone treatment after coronary-artery bypass surgery Klemperer JD Klein I Gomez M Helm RE Ojamaa K Thomas SJ Isom OW Krieger K N Engl J Med 1995 333 1522 1527 10.1056/NEJM199512073332302 7477166 Glucose-insulin-potassium and tri-iodothyronine individually improve hemodynamic performance and are associated with reduced troponin I release after on-pump coronary artery bypass grafting Ranasinghe AM Quinn DW Pagano D Edwards N Faroqui M Graham TR Keogh BE Mascaro J Riddington DW Rooney SJ Townend JN Wilson IC Bonser RS Circulation 2006 114 I245 250 16820580 The role of thyroid hormone therapy in acutely ill cardiac patients Wyne KL Crit Care 2005 9 333 334 1269460 16137376 10.1186/cc3738 Oral triiodothyronine for the prevention of thyroid hormone reduction in adult valvular cardiac surgery Magalhaes AP Gus M Silva LB Schaan BD Braz J Med Biol Res 2006 39 969 978 10.1590/S0100-879X2006000700015 16862288 Effects of intravenous triiodothyronine during coronary artery bypass surgery Guden M Akpinar B Saggbas E Sanisoglu I Cakali E Bayindir O Asian Cardiovasc Thorac Ann 2002 10 219 222 12213743 Does perioperative thyroxine have a role during adult cardiac surgery? Ronald A Dunning J Interact Cardiovasc Thorac Surg 2006 5 166 178 10.1510/icvts.2006.128363 17670541 A trial of thyroxine in acute renal failure Acker CG Singh AR Flick RP Bernardini J Greenberg A Johnson JP Kidney Int 2000 57 293 298 10.1046/j.1523-1755.2000.00827.x 10620211 Thyroxine therapy in patients with severe nonthyroidal illnesses and low serum thyroxine concentration Brent GA Hershman JM J Clin Endocrinol Metab 1986 63 1 8 3011834 Altered thyroid function in nonthyroidal illness and surgery. To treat or not to treat? Utiger RD N Engl J Med 1995 333 1562 1563 10.1056/NEJM199512073332310 7477174 Comment on dangerous dogmas in medicine: the nonthyroidal illness syndrome Caplan RH J Clin Endocrinol Metab 1999 84 2261 2262 10.1210/jc.84.6.2261-a 10372747 Selenium substitution has no direct effect on thyroid hormone metabolism in critically ill patients Angstwurm MW Schopohl J Gaertner R Eur J Endocrinol 2004 151 47 54 10.1530/eje.0.1510047 15248821 SPINA-THYR: A novel systems theoretic approach to determine the secretion capacity of the thyroid gland Dietrich JW Fischer MR Jauch J Pantke E Gärtner R Pickardt CR European Journal of Internal Medicine 1999 10 Suppl 1 S34 Anonymous International Classification of Diseases (ICD) World Health Organization (WHO) http://www.who.int/classifications/icd/en/ Life-threatening thyrotoxicosis. Thyroid storm Burch HB Wartofsky L Endocrinol Metab Clin North Am 1993 22 263 277 8325286 Five new families with resistance to thyroid hormone not caused by mutations in the thyroid hormone receptor beta gene Pohlenz J Weiss RE Macchia PE Pannain S Lau IT Ho H Refetoff S J Clin Endocrinol Metab 1999 84 3919 3928 10.1210/jc.84.11.3919 10566629 Missing Data Analysis: Making It Work in the Real World Graham JW Annu Rev Psychol 2008 18652544 Informed consent of incapable (ICU) patients in Europe: existing laws and the EU Directive Druml C Curr Opin Crit Care 2004 10 570 573 10.1097/01.ccx.0000144765.73540.89 15616403 Deferred consent in emergency intensive care research: what if the patient dies early? Use the data or not? Jansen TC Kompanje EJ Druml C Menon DK Wiedermann CJ Bakker J Intensive Care Med 2007 33 894 900 1964781 17342513 10.1007/s00134-007-0580-8 Gesetz über den Verkehr mit Arzneimitteln (Arzneimittelgesetz – AMG) Anonymous BGBl 2007 I 1066 Directive 2001/20/EC of the European Parliament and of the Council of 4 April 2001 on the approximation of the laws, regulations and administrative provisions of the Member States relating to the implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use Anonymous Off J Eur Communities 2001 L 121 33 44 Commission Directive 2005/28/EC of 8 April 2005 laying down principles and detailed guidelines for good clinical practice as regards investigational medicinal products for human use, as well as the requirements for authorisation of the manufacturing or importation of such products Anonymous Off J Eur Union 2005 L 91 13 19 Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration Vandenbroucke JP von Elm E Altman DG Gotzsche PC Mulrow CD Pocock SJ Poole C Schlesselman JJ Egger M PLoS Med 2007 4 e297 2020496 17941715 10.1371/journal.pmed.0040297 Informed consent for clinical trials in acute coronary syndromes and stroke following the European Clinical Trials Directive: investigators' experiences and attitudes Iwanowski P Budaj A Czlonkowska A Wasek W Kozlowska-Boszko B Oledzka U Maselbas W Trials 2008 9 45 2517587 18644120 10.1186/1745-6215-9-45

Pre-publication history

The pre-publication history for this paper can be accessed here:

http://www.biomedcentral.com/1472-6823/8/13/prepub